Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085813 · ClinicalTrials.gov registry record · Phase 2
Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 11
- Study locations
NCT00085813: Completed Phase 2 study of Non-Small Cell Lung Cancer, sponsored by GlaxoSmithKline.
NCT00085813 is a Phase 2 study of Non-Small Cell Lung Cancer that has completed, run by GlaxoSmithKline. The registered enrollment target is 70 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00085813, a Phase 2 study of Non-Small Cell Lung Cancer, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study was designed to determine how effective and safe Ispinesib is in treating locally advanced or metastatic Non-small Cell Lung cancer in patients who have received a platinum-based chemotherapy and whose disease continues to progress. Treatment involves a 1-hr treatment given intravenously (IV), repeated once every 21 days. A patient may continue treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times over 24 hr period to measure the amount of drug in your body at specific times after the drug is given. Blood samples will also be taken for routine lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment.
Conditions Studied
Interventions
- DRUG Ispinesib
Study Locations (11)
Other
- GSK Investigational Site - Brussels
- GSK Investigational Site - Edegem
- GSK Investigational Site - Leuven
Arizona
- GSK Investigational Site - Scottsdale
Florida
- GSK Investigational Site - Jacksonville
Minnesota
- GSK Investigational Site - Rochester
New York
- GSK Investigational Site - Rochester
North Carolina
- GSK Investigational Site - Greensboro
Pennsylvania
- GSK Investigational Site - Philadelphia
Tennessee
- GSK Investigational Site - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2003-12 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
What the finished NCT00085813 record still lists
NCT00085813 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ispinesib is the first listed.
NCT00085813 lists 11 locations in 9 states (Other, Arizona, Florida).
Frequently Asked Questions
What is clinical trial NCT00085813 about?
NCT00085813 is a clinical study titled "Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer". This study was designed to determine how effective and safe Ispinesib is in treating locally advanced or metastatic Non-small Cell Lung cancer in patients who have received a platinum-based chemotherapy and whose disease continues to progress. Treatment involves a 1-hr treatment given intravenously ...
What is the current status of trial NCT00085813?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2003-12. Estimated completion is 2005-10.
What conditions does trial NCT00085813 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT00085813?
The interventions under investigation include: Ispinesib (DRUG).
Who is sponsoring clinical trial NCT00085813?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00085813 being conducted?
This trial has 11 study locations across Arizona, Florida, Minnesota, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00085813's enrollment target sits among peer trials
70 289th of 454 higher than 161 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia